Neutrophil-to-lymphocyte Ratio (NLR) as a predictor for recurrence in patients with stage III melanoma.

about

Neutrophil-to-lymphocyte Ratio (NLR) as a predictor for recurrence in patients with stage III melanoma.

Item

http://www.wikidata.org/entity/Q52671072

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Neutrophil-to-lymphocyte Ratio ...... ients with stage III melanoma.

@en

Neutrophil-to-lymphocyte Ratio

@nl

type

Item

label

Neutrophil-to-lymphocyte Ratio ...... ients with stage III melanoma.

@en

Neutrophil-to-lymphocyte Ratio

@nl

prefLabel

Neutrophil-to-lymphocyte Ratio ...... ients with stage III melanoma.

@en

Neutrophil-to-lymphocyte Ratio

@nl

P1476

Neutrophil-to-lymphocyte Ratio ...... ients with stage III melanoma.

@en

P2093

Abhijit Ray

http://www.w3.org/2001/XMLSchema#string

Andrew W Hahn

http://www.w3.org/2001/XMLSchema#string

Benjamin O Lawson

http://www.w3.org/2001/XMLSchema#string

Brian Khong

http://www.w3.org/2001/XMLSchema#string

Hung T Khong

http://www.w3.org/2001/XMLSchema#string

James Kuzman

http://www.w3.org/2001/XMLSchema#string

Junjie Ma

http://www.w3.org/2001/XMLSchema#string

Si Xuan

http://www.w3.org/2001/XMLSchema#string

P2860

Sun exposure and risk of melanoma

Final version of 2009 AJCC melanoma staging and classification

Neutrophil-to-lymphocyte ratio as prognostic indicator in gastrointestinal cancers: a systematic review and meta-analysis.

Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients.

Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization

Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines

Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.

Neutrophil to lymphocyte ratio and cardiovascular diseases: a review.

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.

Elevated Blood Neutrophil-to-Lymphocyte Ratio: A Readily Available Biomarker Associated with Death due to Disease in High Risk Nonmetastatic Melanoma.

P304

4044

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41598-018-22425-3

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-03-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29511262

http://www.w3.org/2001/XMLSchema#string

P932

5840418

http://www.w3.org/2001/XMLSchema#string